Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

November 2021; 8 (6) ArticleOpen Access

Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome

View ORCID ProfileJonathan D. Santoro, Lauren M. Kerr, Rachel Codden, Theron Charles Casper, Benjamin M. Greenberg, Emmanuelle Waubant, View ORCID ProfileSek Won Kong, View ORCID ProfileKenneth D. Mandl, Mark P. Gorman
First published September 2, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001079
Jonathan D. Santoro
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan D. Santoro
Lauren M. Kerr
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
BA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lauren.kerr@cardio.chboston.org
Rachel Codden
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rachel.codden@hsc.utah.edu
Theron Charles Casper
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: charlie.casper@hsc.utah.edu
Benjamin M. Greenberg
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: benjamin.greenberg@utsouthwestern.edu
Emmanuelle Waubant
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emmanuelle.waubant@ucsf.edu
Sek Won Kong
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sek Won Kong
  • For correspondence: sekwon.kong@childrens.harvard.edu
Kenneth D. Mandl
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kenneth D. Mandl
  • For correspondence: kenneth.mandl@childrens.harvard.edu
Mark P. Gorman
From the Department of Neurology (J.D.S.), Massachusetts General Hospital, Boston; Department of Neurology (J.D.S., J.M.K., M.P.G.), Boston Children's Hospital, MA; Harvard Medical School (J.D.S., K.D.M.), Boston, MA; Division of Neurology (J.D.S.), Department of Pediatrics, Children's Hospital of Los Angeles, CA; Department of Neurology (J.D.S.), Keck School of Medicine at the University of Southern California, Los Angeles; Department of Pediatrics (R.C., T.C.C.), University of Utah School of Medicine, Salt Lake City; Department of Neurology and Neurotherapeutics (B.M.G.), The University of Texas Southwestern Medical Center at Dallas, TX; UCSF Weill Institute for Neurosciences (E.W.), Department of Neurology, University of California San Francisco, CA; Computational Health Informatics Program (S.W.K., K.D.M.), Boston Children's Hospital, MA; and Department of Pediatrics (S.W.K., K.D.M.), Boston Children's Hospital, MA.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark.gorman@childrens.harvard.edu
Full PDF
Citation
Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome
Jonathan D. Santoro, Lauren M. Kerr, Rachel Codden, Theron Charles Casper, Benjamin M. Greenberg, Emmanuelle Waubant, Sek Won Kong, Kenneth D. Mandl, Mark P. Gorman
Neurol Neuroimmunol Neuroinflamm Nov 2021, 8 (6) e1079; DOI: 10.1212/NXI.0000000000001079

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
608

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Background and Objectives Opsoclonus-myoclonus syndrome (OMS) is a rare autoimmune disorder associated with neuroblastoma in children, although idiopathic and postinfectious etiologies are present in children and adults. Small cohort studies in homogenous populations have revealed elevated rates of autoimmunity in family members of patients with OMS, although no differentiation between paraneoplastic and nonparaneoplastic forms has been performed. The objective of this study was to investigate the prevalence of autoimmune disease in first-degree relatives of pediatric patients with paraneoplastic and nonparaneoplastic OMS.

Methods A single-center cohort study of consecutively evaluated children with OMS was performed. Parents of patients were prospectively administered surveys on familial autoimmune disease. Rates of autoimmune disease in first-degree relatives of pediatric patients with OMS were compared using Fisher exact t test and χ2 analysis: (1) between those with and without a paraneoplastic cause and (2) between healthy and disease (pediatric multiple sclerosis [MS]) controls from the United States Pediatric MS Network.

Results Thirty-five patients (18 paraneoplastic, median age at onset 19.0 months; 17 idiopathic, median age at onset 25.0 months) and 68 first-degree relatives (median age 41.9 years) were enrolled. One patient developed systemic lupus erythematosus 7 years after OMS onset. Paraneoplastic OMS was associated with a 50% rate of autoimmune disease in a first-degree relative compared with 29% in idiopathic OMS (p = 0.31). The rate of first-degree relative autoimmune disease per OMS case (14/35, 40%) was higher than healthy controls (86/709, 12%; p < 0.001) and children with pediatric MS (101/495, 20%; p = 0.007).

Discussion In a cohort of pediatric patients with OMS, there were elevated rates of first-degree relative autoimmune disease, with no difference in rates observed between paraneoplastic and idiopathic etiologies, suggesting an autoimmune genetic contribution to the development of OMS in children.

Glossary

OMS=
opsoclonus-myoclonus syndrome;
BCH=
Boston Children's Hospital;
DTaP=
diphtheria, tetanus, pertussis;
IQR=
interquartile range;
MMR=
measles, mumps, rubella;
MS=
multiple sclerosis;
NPMSC=
Network of Pediatric MS Centers

Opsoclonus-myoclonus syndrome (OMS) is a rare autoimmune disorder characterized by the triad of involuntary rapid eye movements, myoclonus, and ataxia.1 Roughly 50% of cases in children are paraneoplastic (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma), whereas the remainder are infection associated or idiopathic.1,2 Based on CSF findings, pathologic studies, and response to immunosuppressive therapy, OMS is considered to be an autoimmune disorder.

One approach to understanding the underlying pathogenic mechanisms in autoimmune disorders is to examine whether there are associated comorbid personal and familial autoimmune diseases. One European study reported autoimmune disease in 15.8% of parents of children with OMS compared with 2% of control parents.3 This finding has not been assessed in other OMS populations, nor have there been comparisons of autoimmune family histories between patients with and without a paraneoplastic etiology.

This study sought to investigate the prevalence of autoimmune diseases in first-degree relatives of pediatric patients with OMS and to compare the rate (1) between those with and without a paraneoplastic cause and (2) to the comparable rates in healthy and disease (pediatric multiple sclerosis [MS]) controls.

Methods

Standard Protocol Approvals, Registrations, and Patient Consents

This study was approved by the Institutional Review Board (IRB) at Boston Children's Hospital (BCH). Following approval, all patients with OMS who were subsequently seen in the senior author's (M.P.G.) clinic were offered enrollment between April 2018 and March 2019 (dates of first and last enrollment). Consent, and where appropriate assent (ages 7–17 years), was obtained for study participation.

Data Collection

Clinical information for patients was abstracted retrospectively using a predetermined case report form through chart review of institutional and outside medical records when available (eAppendix 1, links.lww.com/NXI/A577). CSF data collected included white blood cell count (range 0–5 cells/mm3) with differential and oligoclonal banding (abnormal if present). First-degree relative was defined as a biologic parent or sibling. Family autoimmune disease was collected prospectively by administering a survey with highly prevalent autoimmune diseases listed to parents of patients (eAppendix 2, links.lww.com/NXI/A578). The same survey had been used in an IRB-approved study of familial autoimmune disease in pediatric MS in the Network of Pediatric MS Centers (NPMSC) with data collected prospectively in a longitudinal cohort at 18 centers (including BCH) enrolled from May 2011 to July 2017.

Statistical Analysis

Mean and median values were calculated for all continuous variables, and frequency (expressed as a percentage of the total population) was calculated for noncontinuous variables. For continuous variables, Welch t tests and Mann-Whitney U tests were used to compare means. Interquartile ranges were calculated for continuous variables. The Fisher exact test was used to compare prevalence of autoimmune disease between patients with paraneoplastic and idiopathic OMS. The rate of first-degree relative autoimmune disease on a case level in the OMS cohort was compared using χ2 analysis to the same rates found in patients with pediatric MS and autoimmune disease-free controls in the NPMSC study. For a sensitivity analysis, we also used the BCH-specific data for comparison. Age at onset of first-degree relative autoimmune disease was compared between the OMS cohort and comparator groups using a Mann-Whitney U test. A nominal p value of <0.05 was considered statistically significant for each statistical test.

Data Availability

Deidentified data, statistical analysis, and study documents will be available on request to qualified researchers pending IRB approval.

Results

Thirty-five patients and 68 first-degree relatives (biological parents) were enrolled. Two parents (of different patients) were not available. No siblings were reported to have autoimmune disease (n = 43, median age 3.8 years [interquartile range [IQR]: 2.5–7.4]). Demographic and clinical data are reported in Table 1. The median follow-up time for individuals with OMS was 8.11 years (IQR: 2.8–11.5 years). Eighteen patients had paraneoplastic OMS (median age at onset 19.0 months, IQR 11.7–24.0 months), and 17 patients had nonparaneoplastic OMS (median onset 25.0 months, IQR 20–72.5 months) (p = 0.019 for age at onset). All tumors were of neural crest cell origin, with neuroblastoma being the most common (55%). There were no significant differences between groups with regard to preceding infection, CSF white blood cell number, or presence of CSF oligoclonal bands (Table 1). All patients vaccinated within 4 weeks of symptom onset (n = 4) were diagnosed with nonparaneoplastic OMS, although the specific vaccine(s) administered was different in each case (diphtheria, tetanus, pertussis [DTaP], Prevnar 13/Hepatitis A, DTaP/measles, mumps, rubella [MMR]/Haemophilus, and MMR/varicella zoster virus [VZV]). Paraneoplastic OMS had a rate of 50% of autoimmune disease in a first-degree relative compared with 29% in nonparaneoplastic OMS (x2 [1, N = 34] = 1.54, p = 0.31).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

Demographics and Clinical Features

Patient and family autoimmune diseases are presented in Table 2. One patient in our cohort developed systemic lupus erythematosus 7 years after nonparaneoplastic OMS diagnosis and treatment. Fourteen patients (40%) had at least 1 first-degree family member with an autoimmune disease, accounting for 21% of all parents with children with OMS. Compared with previously published data,3 this cohort had a similar rate of familial autoimmune disease (13/82, 15.2%; x2 [1, N = 149] = 0.56, p = 0.45). The most common autoimmune diseases among first-degree relatives were thyroid disease (n = 8/68, 12%), followed by type 1 diabetes and inflammatory bowel disease (n = 3/68, 4% and n = 2/68, 3%, respectively). The majority (n = 12/14, 86%) of first-degree relatives with autoimmune disease were female (x2 [1, N = 67] = 5.79, p = 0.016).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2

Autoimmune Diseases in Cohort vs NPMSC MS and Healthy Controls

The rate of first-degree relative autoimmune disease was significantly higher in the OMS cohort (n = 14/35, 40%) compared with the same rate in the pediatric MS (n = 101/495, 20%) (x2 [1, N = 530] = 7.39, p = 0.007) and healthy control cohorts (n = 86/709, 12%) (x2 [1, N = 734] = 22.27, p < 0.001) (Figure). The comparison did not change significantly when using BCH site-specific level for pediatric MS (n = 8/36, 22%) and healthy controls (n = 11/77, 14%).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Prevalence of Autoimmune Disease by Cohort

Age at onset for autoimmune disease in first-degree relatives in the OMS cohort was 30 years and was significantly younger compared with the age at onset (34 years) in the combined group of first-degree relatives with autoimmune disease in the pediatric MS and healthy control cohorts (p < 0.001, 95% CI: 5.49–6.51). Sixty-four percent of first-degree relatives had onset before birth of the proband with OMS.

Discussion

This study identified high rates of familial autoimmune disease in patients with both paraneoplastic and nonparaneoplastic OMS. When analyzed on a per-parent basis to allow for comparison, the rate of autoimmune disease in our study (14/68, 21%) was similar to a prior study in OMS (13/82, 15.8%, p = 0.45).3

Our study adds to the growing literature that the paraneoplastic and nonparaneoplastic forms of OMS are more similar than different.3 We identified no difference in rates of familial autoimmune disease between paraneoplastic and nonparaneoplastic forms of OMS. One proposed hypothesis to explain nonparaneoplastic cases is that the host immune response eliminated a previous neural crest cell tumor, which therefore would not be detected at OMS onset. From this perspective, high rates of familial autoimmune disease suggest that the antitumor immune response in OMS may be driven by variants in genes involved in autoimmune disease. The oncologic outcome of neuroblastoma is significantly better in children with OMS compared with those without OMS. Further understanding of specific genetic variants that contribute to OMS expression in neuroblastoma may provide a window into harnessing the salutary effects of the immune system response to neuroblastoma more generally.

An alternative hypothesis is that there are different triggers in nonparaneoplastic compared with paraneoplastic cases, with infections being commonly reported. However, rates of preceding infection did not differ between the paraneoplastic and nonparaneoplastic subgroups in our study. This finding, along with high rates of familial autoimmune disease in both subgroups, suggests that the expression of OMS may be driven more by genetic susceptibility than the specific antigenic trigger.

Our cohort also captured a higher rate of autoimmune disease in first degree than in pediatric MS and healthy controls. We also report the post-OMS development of systemic lupus erythematosus in a patient. These results are of even greater importance in the context of the younger age at onset for OMS, allowing for less time for parental development of autoimmune disease. The majority of parents had onset of their autoimmune disorder before the birth of the proband with OMS. There are emerging data on the role of maternal immune activation contributing to the development of both autoimmune disease and neuropsychiatric disease in offspring. Whether this plays a role in OMS requires further research.4

Our results can be viewed within the context of existing literature demonstrating the role of genetic susceptibility in a variety of autoimmune diseases in children.5,-,8 One prior study showed higher rates of the HLA-DRB1*01 allele in children with OMS (with or without neuroblastoma) compared with controls.6 Further studies using modern genetic techniques such as whole-genome sequencing assessing a wider array of genes may identify additional genes involved in the development of OMS. The variety of autoimmune disease captured in this study supports the theory that multiple genes and related immune pathways may be at play.9,10

This study is not without limitation. Our sample size was comparable to other studies in OMS, but nonetheless small, in part owing to the rarity of OMS. Recall bias cannot be excluded in familial reporting of autoimmune diseases, which potentially confounds our data. Diagnoses in relatives were not verified by direct review of their medical records. Probands in this study had prolonged follow-up (median: 8.11 years), although given that the majority of autoimmune diseases present in early adulthood, it is possible that the rate of autoimmune disease reported in them and their siblings may be underestimated. Controls could not have an autoimmune disorder, which may have decreased the rate of parental autoimmune disease; however, this restriction did not apply to the pediatric patients with MS. We did not include a group of children with neuroblastoma without OMS, which would be an important topic for future work. Finally, the reporter (mother vs father) of family history of autoimmune disease was not recorded in this study and may potentially affect the quality of data reported.

In a cohort of pediatric patients with OMS, elevated rates of first-degree autoimmune disease exist without significant differences in rates between paraneoplastic and nonparaneoplastic forms. These data suggest that genetic predisposition may be more important than the triggering antigen in the pathogenesis of OMS. Further genetic interrogation in this population is warranted.

Study Funding

This study was supported by the Precision Link Biobank for Health Discovery at Boston Children's Hospital and Pfizer, Inc.

Disclosure

J.D. Santoro reports receiving research funding from the Race to Erase MS Foundation, Thrasher Foundation, and National Institutes of Health. L. Kerr, R. Codden, T.C. Casper, B.M. Greenberg, E. Waubant, S.W. Kong, and K.M. Mandl report no disclosures. M.P. Gorman reports receiving research funding from Roche as a pediatric multiple sclerosis clinical trial site. Go to Neurology.org/NN for full disclosures.

Acknowledgment

The authors thank all collaborators through the US Network of Pediatric MS Centers who provided data for statistical comparison.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the authors.

  • Received April 5, 2021.
  • Accepted in final form June 8, 2021.
  • Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Ratner N,
    2. Brodeur GM,
    3. Dale RC,
    4. Schor NF
    . The “neuro” of neuroblastoma: neuroblastoma as a neurodevelopmental disorder. Ann Neurol. 2016;80(1):13-23.
    OpenUrlCrossRef
  2. 2.↵
    1. Matthay KK,
    2. Blaes F,
    3. Hero B, et al.
    Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett. 2005;228:275-282.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Krasenbrink I,
    2. Fühlhuber V,
    3. Juhasz-Boess I, et al
    . Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS). Neuropediatrics. 2007;38:114-116.
    OpenUrlPubMed
  4. 4.↵
    1. Jones HF,
    2. Ho ACC,
    3. Sharma S, et al
    . Maternal thyroid autoimmunity associated with acute-onset neuropsychiatric disorders and global regression in offspring. Dev Med Child Neurol. 2019;61(8):984-988.
    OpenUrl
  5. 5.↵
    1. Ceccarelli F,
    2. Agmon-Levin N,
    3. Perricone C
    . Genetic factors of autoimmune diseases. J Immunol Res. 2016;2016:3476023.
    OpenUrl
  6. 6.↵
    1. Li YR,
    2. Li J,
    3. Zhao SD, et al
    . Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015;21:1018-1027.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Hero B,
    2. Radolska S,
    3. Gathof BS
    . Opsomyoclonus syndrome in infancy with or without neuroblastoma is associated with HLA DRB1*01 [Abstract]. Pediatr Blood Cancer. 2005;45:S365-S588.
    OpenUrl
  8. 8.↵
    1. Pociot F,
    2. Lernmark Å
    . Genetic risk factors for type 1 diabetes. Lancet. 2016;387:2331-2339.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Pranzatelli MR,
    2. Travelstead AL,
    3. Tate ED, et al
    . B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes.. Neurology. 2004;62:1526-1532.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Pranzatelli MR,
    2. Travelstead AL,
    3. Tate ED, et al
    . Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonus. J Pediatr Hematol Oncol. 2004;26:718-723.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Study Funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Neuro-ophthalmology
  • All Immunology
  • Autoimmune diseases
  • Paraneoplastic syndrome

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Clinical features of neuromyelitis optica in children
    US Network of Pediatric MS Centers report
    Tanuja Chitnis, Jayne Ness, Lauren Krupp et al.
    Neurology, December 18, 2015
  • Article
    Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
    Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo et al.
    Neurology: Neuroimmunology & Neuroinflammation, May 18, 2021
  • Article
    Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts
    Completing the picture
    Zachary A. Miller, Virginia E. Sturm, Gamze Balci Camsari et al.
    Neurology: Neuroimmunology & Neuroinflammation, October 28, 2016
  • Clinical/Scientific Notes
    Multiple sequential antibody-associated syndromes with a recurrent mutated neuroblastoma
    Ali Amini, Bethan Lang, Dominic Heaney et al.
    Neurology, July 06, 2016
Neurology - Neuroimmunology Neuroinflammation: 10 (6)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise